Molecular markers and prostate cancer prognosis

Clinical Prostate Cancer

Volumn 3, Issue 3, 2004, Pages 157-164

  Chin, Jonathan L ^a   Reiter, Robert E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Fluorescence in situ hybridization; Immunohistochemistry; Proteasome; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; CAVEOLIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; KI 67 ANTIGEN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE STEM CELL ANTIGEN; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN;

CANCER MORTALITY; CANCER RADIOTHERAPY; CAUSE OF DEATH; CELL PROLIFERATION; CHROMOSOME 17P; CHROMOSOME 8Q; GENE OVEREXPRESSION; HUMAN; MOLECULAR BIOLOGY; MULTIVARIATE ANALYSIS; ONCOGENE; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 11144240494     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2004.n.026     Document Type: Review

References (77)

1. American Cancer Society, Cancer Facts & Figures 2004. Atlanta, GA: ACS, 2004.
2. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med 2004; 350:2239-2246.
3. Pollack A, Cowen D, Troncoso P, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003; 97:1630-1638.
4. Halvorsen OJ, Haukaas S, Hoisaeter PA, et al. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res 2001; 21:4071-4076.
5. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156:1064-1068.
6. Matsuura H, Hayashi N, Kawamura J, et al. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation. Eur Urol 2000; 37:212-217.
7. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22:8590-8607.
8. Huang A, Gandour-Edwards R, Rosenthal SA, et al. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 1998; 51:346-351.
9. Scherr DS, Vaughan ED Jr, Wei J, et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999; 162:12-16.
10. Wu TT, Hsu YS, Wang JS, et al. The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan. J Urol 2003; 170:78-81.
11. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999; 162:2040-2045.
12. Borre M, Stausbol-Gron B, Nerstrom B, et al. Immunohistochemical BCL-2 and Ki-67 expression predicr survival in prostate cancer patients followed expectantly. Prostate Cancer Prostatic Dis 1998; 1:268-275.
13. Ivanovic V, Melman A, Davis-Joseph B, et al. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1995; 1:282-284.
14. Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001; 19:2856-2864.
15. Wikstrom P, Stattin P, Franck-Lissbrant I, et al. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37:19-29.
16. Kim IY, Ahn HJ, Lang S, et al. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998; 4:1625-1630.
17. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992; 52:5104-5109.
18. Li LC, Zhao H, Nakajima K, et al. Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol 2001; 166:705-709.
19. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54:3929-3933.
20. Loric S, Paradis V, Gala JL, et al. Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. Eur J Cancer 2001; 37:1475-1481.
21. Verhage BA, van Houwelingen K, Ruijter TE, et al. Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer 2002; 100:683-685.
22. Jonsson BA, Adami HO, Hagglund M, et al. -160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer 2004; 109:348-352.
23. Tsukino H, Kuroda Y, Imai H, et al. Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer. Urol Int 2004; 72:203-207.
24. Noordzij MA, van Steenbrugge GJ, Schroder FH, et al. Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 1999; 84:478-483.
25. Vis AN, Noordzij MA, Fitoz K, et al. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000; 164:2156-2161.
26. Coradini D, Daidone MG. Biomolecular prognostic factors in breast cancer. Curr Opin Obstet Gynecol 2004; 16:49-55.
27. Signotetti S, Montironi R, Manola J, et al. HER2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92:1918-1925.
28. Mark HF, Feldman D, Das S, et al. Fluorescence in situ hybridization study of HER2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 1999; 66:170-178.
29. Fossa A, Lilleby W, Fossa SD, et al. Independent prognostic significance of HER2 oncoprotein expression in pNO prostate cancer undergoing curative radiotherapy. Int J Cancer 2002; 99:100-105.
30. Morote J, de Torres I, Caceres C, et al. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer 1999; 84:421-425.
31. Ross JS, Sheehan CE, Hayner-Buchan AM, et al. Prognostic significance of HER2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79:2162-2170.
32. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
33. Morris MJ, Reuter VE, Kelly WK, et al. HER2 profiling and targeting in prostate carcinoma. Cancer 2002; 94:980-986.
34. Borre M, Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000; 164:716-721.
35. Deliveliotis C, Skolarikos A, Karayannis A, et al. The prognostic value of p53 and DNA ploidy following radical prostatectomy. World J Urol 2003; 21:171-176.
36. Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000; 60:1585-1594.
37. Ritter MA, Gilchrist KW, Voytovich M, et al. The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53:574-580.
38. Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997; 89:158-165.
39. Omar EA, Behlouli H, Chevalier S, et al. Relationship of p21 (WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate 2001; 49:191-199.
40. Rigaud J, Tiguert R, Decobert M, et al. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. Prostate 2004; 58:269-276.
41. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
42. McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59:4291-4296.
43. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003; 9:1474-1479.
44. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003; 2:S169-S177.
45. Gao N, Zhang Z, Jiang BH, et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003; 310:1124-1132.
46. Thomas GV, Schrage MI, Rosenfelt L, et al. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol 2000; 164:1987-1991.
47. Ribal MJ, Fernandez PL, Lopez-Guillermo A, et al. Low p27 expression predicts biochemical relapse after radical prostatectomy in patients with clinically localised prostate cancer. Anticancer Res 2003; 23:5101-5106.
48. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159:941-945.
49. Freedland SJ, deGregorio F, Sacoolidge JC, et al. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 2003; 169:1325-1330.
50. Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002; 8:3419-3426.
51. Jenkins RB, Qian J, Lieber MM, et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57:524-531.
52. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4:223-238.
53. Sato K, Qian J, Slezak JM, et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999; 91:1574-1580.
54. Tsuchiya N, Slezak JM, Lieber MM, et al. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer 2002; 34:363-371.
55. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998; 95:1735-1740.
56. Reiter RE, Sato I, Thomas G, et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 2000; 27:95-103.
57. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19:1288-1296.
58. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-629.
59. Rhodes DR, Sanda MG, Otte AP, et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95:661-668.
60. Yang G, Truong LD, Wheeler TM, et al. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 1999; 59:5719-5723.
61. Satoh T, Yang G, Egawa S, et al. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 2003; 97:1225-1233.
62. Tahir SA, Ren C, Timme TL, et al. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 2003; 9:3653-3659.
63. Li J, White N, Zhang Z, et al. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol 2004; 171:1782-1787.
64. Banez LL, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003; 170:442-446.
65. Petricoin EF III, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94:1576-1578.
66. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609-3614.
67. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin in Chem Biol 2002; 6:493-500.
68. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-685.
69. Williams S, Pettaway C, Song R, et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003; 2:835-843.
70. Ikezoe T, Yang Y, Saito T, et al. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 2004; 95:271-275.
71. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108-2121.
72. Visakorpi T, Kallioniemi AH, Syvanen AC, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995; 55:342-347.
73. Cher ML, Bova GS, Moore DH, et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996; 56:3091-3102.
74. Alers JC, Krijtenburg PJ, Rosenberg C, et al. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 1997; 77:437-448.
75. Zheng Y, Xu Y, Ye B, et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 2003; 98:2576-2582.
76. Chin JL, Reiter RE. Genetic alterations in prostate cancer. Curr Urol Rep 2004; 5:157-165.
77. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.